Equities research analysts expect Zymeworks Inc (NASDAQ:ZYME) to announce earnings per share (EPS) of ($0.62) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Zymeworks’ earnings. The firm is scheduled to issue its next earnings results on Monday, August 21st.

According to Zacks, analysts expect that Zymeworks will report full-year earnings of ($3.10) per share for the current financial year. For the next fiscal year, analysts expect that the firm will report earnings of ($2.53) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Zymeworks.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings data on Monday, May 15th. The company reported ($1.13) earnings per share (EPS) for the quarter. Zymeworks had a negative return on equity of 798,487.60% and a negative net margin of 6,924.35%. The firm had revenue of $0.23 million during the quarter.

Several brokerages recently issued reports on ZYME. Canaccord Genuity began coverage on Zymeworks in a research note on Tuesday, May 23rd. They issued a “buy” rating and a $18.00 price objective on the stock. Barclays PLC began coverage on Zymeworks in a research report on Tuesday, May 23rd. They set an “overweight” rating and a $20.00 target price on the stock. Wells Fargo & Company began coverage on Zymeworks in a research report on Tuesday, May 23rd. They set an “outperform” rating and a $20.00 target price on the stock. Finally, Citigroup Inc. began coverage on Zymeworks in a research report on Tuesday, May 23rd. They set a “buy” rating and a $18.00 target price on the stock.

Zymeworks (NASDAQ:ZYME) traded down 1.68% on Monday, reaching $9.35. 4,629 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $11.81 and a 200-day moving average of $11.81. The company’s market cap is $233.19 million. Zymeworks has a 12-month low of $7.24 and a 12-month high of $14.25.

TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/06/19/0-62-earnings-per-share-expected-for-zymeworks-inc-zyme-this-quarter.html.

Zymeworks Company Profile

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Get a free copy of the Zacks research report on Zymeworks (ZYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with MarketBeat.com's FREE daily email newsletter.